T1	Participants 431 465	Patients in stage IIIB or IV NSCLC
T2	Participants 784 866	105 (GA arm, 51; PG arm, 54) eligible patients (stage IV, 32 and 30, respectively)
T3	Participants 1720 1748	advanced or metastatic NSCLC
